A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

Exclusion Criteria

• •History of cancer
• •History of treated diabetic gastroparesis
• •Current biliary disease or history of pancreatitis
• •History of significant GI surgery
• •Recent clinically significant cardiovascular and/or cerebrovascular disease
• •Hypertension
• •History of human immunodeficiency virus infection
• •History of or current liver disease or acute symptomatic infection with hepatitis B or hepatitis C
• •History of alcohol or substance abuse
• •Female subject is pregnant, lactating, or \<6 weeks postpartum
• •Known allergy to any GLP 1 analogue, liraglutide, other study medications' excipients, excipients of albiglutide, or Baker's yeast
• •History of type 1 diabetes mellitus
• •Contraindications (as per the prescribing information) for the use of either background or potential randomized study medications (e.g., liraglutide)
• •Receipt of any investigational drug or liraglutide within the 30 days or 5 half lives, whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies
• •History or family history of thyroid disease